Generation of a Plasma Microrna (Mirna) Signature Predicting Response to Metronomic Chemotherapy (Mc) for Advanced Breast Cancer (Abc)

Emmenegger, Urban; Sousa, Berta; Hoang, Van; Chow, Albert H.L.; Clemons, M; Dent, Susan; Wong, Nicolas; Kerbel, R.S.; Trudeau, M.; Slingerland, J.; Eisen, Andrew; Ebos, John M.L.; Chan, KW; Gardner, S.; Pritchard, K. I.

doi:10.1093/annonc/mdu326.12

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emmenegger et al 125 generated a predictive plasma miRNA signature of response to metronomic chemotherapy. They analysed pretreatment plasma samples from patients with advanced-stage breast cancer classified as high responders to dalCMP treatment versus patients who were refractory to dalCMP using the nCounter® miRNA expression assay (NanoString Technologies).…”

Section: Biomarkers Of Clinical Responsementioning

confidence: 99%

Clinical overview of metronomic chemotherapy in breast cancer

2015

View full text Add to dashboard Cite

Over 15 years ago, low-dose metronomic chemotherapy was shown to induce disease control in patients with advanced-stage breast cancer with a lower incidence of adverse events compared with conventional maximum tolerated dose chemotherapy. Good response rates have been seen in heavily pre-treated patients for whom limited treatment options are available. Most patients prefer oral therapy and metronomic chemotherapy is a convenient alternative in patients with advanced-stage disease in which minimal toxicity and good tumour control are the overall aims of treatment. The addition of metronomic protocols to standard neoadjuvant chemotherapy regimens has produced promising pathological complete response rates. Ongoing trials including the SYSUCC-001 trial in patients with triple-negative breast cancer and the IBCSG 22-00 trial that is assessing a cyclophosphamide-methotrexate maintenance regimen after standard adjuvant therapy in hormone receptor-negative disease, will clarify the value of adding this approach to conventional therapies. The low cost associated with metronomic chemotherapy represents an opportunity for the utilization of this treatment option, especially in developing countries, and poses a challenge for the launch of large trials sponsored by industry. Using breast cancer as the principal example, we discuss the key clinical advances in this area, including new trial design, appropriate patient and end point selection, as well as the evolving rationale for metronomic chemotherapy combinations.

show abstract

Section: Biomarkers Of Clinical Responsementioning

confidence: 99%

Clinical overview of metronomic chemotherapy in breast cancer

2015

View full text Add to dashboard Cite

show abstract

“…In cell culture, it was demonstrated that hsa-miR-451a sensitizes breast cancer cells to tamoxifen or carboplatin therapy [140,141] or suppress cancer growth by blocking tumor-promoting genes [142,143]. Nevertheless, some studies have described the presence of higher hsa-miR-451a levels in the plasma of breast or ovarian cancer patients [144][145][146]. In particular, the study of and controls and found the hsa-mir-451a was overexpressed in the patient groups [147].…”

Section: Top Abundant Cf-mirna Regions In Plasma Of Bc Patientsmentioning

confidence: 99%

“…Other miRNAs abundantly expressed in the plasma of the BC cohort of this thesis have been related to tumor-related features. For example, hsa-miR-150-5p was upregulated in plasma samples of cancer patients [144,168,169]. The hsa-miR-122-5p was included in minimally invasive panels for early detection of breast and gastric cancers [76,[170][171][172].…”

Section: Top Abundant Cf-mirna Regions In Plasma Of Bc Patientsmentioning

confidence: 99%

“…Despite hsa-miR-122-5p, hsa-miR-23c, or hsa-miR-320e have not the highest fold change values, they are more likely to be detected in less sensitive techniques such as quantitative real-time polymerase chain reaction (qRT-PCR). In particular, the hsa-miR-122-5p has been identified in liquid biopsies of BC patients, especially in more aggressive subtypes and models [76,144,196,197]. Interestingly, Gallo et al (2022) demonstrated that mesenchymal stem cells (MSCs) export hsa-miR-23c which seems to control the growth of TNBC cells [198].…”

Section: Relevant Cf-mirna Regions In Tnbc Patientsmentioning

confidence: 99%

“…The hsa-miR-497-5p was indicated as a contributor to the immune evasion of breast cancer cells by targeting CD274 [200], and independent studies suggested targeting this miRNA as a novel strategy to treat breast and ovarian cancers [201,202]. Then, another study involving nCounter technology for evaluating circulating miRNA of advanced BC patients determined that hsa-miR-548ai contributes to the treatment response prediction [144]. About hsa-miR-1271-5p, different levels of this miRNA were found in BC subtypes in Brazilian patients, and the HER2+ subtype showed the most homogeneous values [203].…”

Section: Relevant Cf-mirna Regions In Her2+ Bc Patientsmentioning

confidence: 99%

See 2 more Smart Citations

Heterogeneidade relacionada ao câncer de mama representada em miRNAs circulantes e vesiculares: resultados de ensaios de alto rendimento e prova de conceito para seleção de vesículas extracelulares derivadas de tumor

Carrasco

View full text Add to dashboard Cite

Esse doutorado foi o resultado de um longo caminho de aprendizado e crescimento, não apenas científico, mas também pessoal. Assim, gostaria de agradecer a todas as pessoas que contribuíram de diversas formas a conseguir essa realização.Em princípio, agradecer ao Prof. Roger Chammas e a Luciana (Lu) Andrade pela grande oportunidade de participar no projeto "Retratos da Mama" e contribuir através do desenvolvimento desta tese. Obrigado por todos os conselhos, sessões de discussão, viagens, apresentações, oportunidades de colaboração e mensagens de apoio.Gostaria também de agradecer a Tatiane (Tuty) Furuya e a Miyuki Uno por serem o meu primeiro contato no lab, por me acolherem e por me guiar na minha inserção ao Centro de Investigação Translacional em Oncologia (CTO). Um passo que logo se tornou uma série de colaborações, com excelentíssimas pessoas e grandes aprendizados. Muito obrigado! Assim, aproveito a ocasião para mostrar a minha gratidão ao Curso em Oncologia Molecular (https://www.cursooncologia.com.br/), o evento que me abriu as portas, me permitiu conhecer o CTO e o Instituto do Câncer do Estado de São Paulo (ICESP), e saber da qualidade dos profissionais que trabalham neste local, que se transparece através de suas conquistas. Parte dessa gratidão foi retribuída na minha participação nas comissões que organizaram a V e VI edição desse curso. Especial agradecimento à Ana Carolina, Gláucia, Isabela, Jean, Lívia, Nadine, Nathália, Pedro e Vinícius (Vini), colegas da pós-graduação, que participaram na parceria para mover as engrenagens para organizar um curso, um simpósio, e delinear a escrita de um livro de conceitos em Oncologia (da molécula à clínica), no contexto da maior alteração mundial que nós fez trabalhar a distância, mas sempre juntos.De fato, a produção do livro (https://lnkd.in/ejWKwKts), em companhia dos membros do CTO, e guiados pelos editores (Prof. Roger Chammas, Profa. Luisa Villa, e Profa. Maria Aparecida Koike), contribui enormemente à consolidação dos nossos conhecimentos e à canalização dessa informação para as novas gerações.Aproveito em agradecer aos membros do CTO e o nosso sistema de pós-graduação por todas as sugestões fornecidas ao projeto nas diferentes apresentações, bem como na jornada acadêmica em Oncologia. vii Palavras-chave: miRNA, câncer de mama, biópsia líquida, vesículas extracelulares, proteínas de ligação a glicanos, ensaios de triagem em larga escala.

show abstract

Current achievements and future perspectives of metronomic chemotherapy

Romiti¹,

Falcone²,

Roberto³

et al. 2016

Invest New Drugs

View full text Add to dashboard Cite

In recent years, many anticancer drugs have been tested at metronomic dosages for a variety of tumours. Mechanisms of action attributed to metronomic chemotherapy (MCT) include antiangiogenesis, immunomodulation, direct inhibition of tumour growth, effect on tumour initiating cells and the modulation of clonal evolution. An active clinical research, aimed at testing MCT in several cancers, has been conducted over the past 15 years. However, because the majority of available results come from earlier phase II studies, mainly performed in the area of breast cancer (BC), it is clear that there are areas still to be investigated. We considered current studies dealing with MCT according to the clinical setting of patients. Despite a certain degree of overlap, we were able to identify four main clinical indications for MCT: refractory disease and frailty of patients, advanced stage disease (requiring first and second-line therapy), early stage disease and maintenance therapy after induction chemotherapy. In addition, a section of this review has been addressed to the combination of MCT with immunotherapy following the growing interest in the reinstatement of immune-surveillance. Crucial questions, such as the definition of optimal schedules of continuously delivered, low-dose chemotherapy and the recognition and validation of predictive biomarkers, need to be further addressed. Moreover, comparisons with the best supportive care are especially lacking and thus urgently awaited to establish the key role of MCT in the care of pretreated and frail patients. Maintenance therapy promises to be one of the most worthwhile developments for MCT. Currently, several combination strategies with standard chemotherapy, target agents or immunotherapy are under investigation but further efforts are needed to fill the gaps of knowledge in this field.

show abstract

Generation of a Plasma Microrna (Mirna) Signature Predicting Response to Metronomic Chemotherapy (Mc) for Advanced Breast Cancer (Abc)

Cited by 3 publications

References 0 publications

Clinical overview of metronomic chemotherapy in breast cancer

Clinical overview of metronomic chemotherapy in breast cancer

Heterogeneidade relacionada ao câncer de mama representada em miRNAs circulantes e vesiculares: resultados de ensaios de alto rendimento e prova de conceito para seleção de vesículas extracelulares derivadas de tumor

Current achievements and future perspectives of metronomic chemotherapy

Contact Info

Product

Resources

About